Examorelin substantially and dose-dependently increases [[Blood plasma|plasma]] levels of [[growth hormone]] (GH) in animals and humans.<ref name="Imbimbo Mant Edwards Amin 1994" /> In addition, similarly to [[pralmorelin]] (GHRP-2) and GHRP-6, it slightly and dose-dependently stimulates the release of [[prolactin]], [[adrenocorticotropic hormone]] (ACTH), and [[cortisol]] in humans.<ref name="Imbimbo Mant Edwards Amin 1994" /><ref name="Arvat Vito Maccagno Broglio 1997 pp. 885–891">{{cite journal | last=Arvat | first=Emanuela | last2=Vito | first2=Lidia Di | last3=Maccagno | first3=Barbara | last4=Broglio | first4=Fabio | last5=Boghen | first5=Muni F | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Effects of GHRP | journal=Peptides | publisher=Elsevier BV | volume=18 | issue=6 | year=1997 | pages=885–891 | url=https://dx.doi.org/10.1016/S0196-9781(97)00016-8 | doi=10.1016/s0196-9781(97)00016-8 | accessdate=2015-06-12}}</ref> There are conflicting reports on the ability of examorelin to elevate [[insulin-like growth factor 1]] (IGF-1) and [[insulin-like growth factor-binding protein 1]] (IGFBP-1) levels in humans, with some studies finding no increase and others finding a slight yet statistically significant increase.<ref name="Imbimbo Mant Edwards Amin 1994" /><ref name="Ghigo Arvat Gianotti Grottoli 1996 pp. 407–412">{{cite journal | last=Ghigo | first=E | last2=Arvat | first2=E | last3=Gianotti | first3=L | last4=Grottoli | first4=S | last5=Rizzi | first5=G | last6=Ceda | first6=G. | last7=Boghen | first7=M. | last8=Deghenghi | first8=R | last9=Camanni | first9=F | title=Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging | journal=European Journal of Endocrinology | publisher=BioScientifica | volume=135 | issue=4 | year=1996 | pages=407–412 | url=https://dx.doi.org/10.1530/eje.0.1350407 | doi=10.1530/eje.0.1350407 | accessdate=2015-06-12}}</ref><ref name="Laron Frenkel Deghenghl Anin 1995 pp. 631–635">{{cite journal | last=Laron | first=Z. | last2=Frenkel | first2=J. | last3=Deghenghl | first3=R. | last4=Anin | first4=S. | last5=Klinger | first5=B. | last6=Siibergeld | first6=A. | title=Intranasal administration of the GHRP | journal=Clinical Endocrinology | publisher=Wiley-Blackwell | volume=43 | issue=5 | year=1995 | pages=631–635 | url=https://dx.doi.org/10.1111/j.1365-2265.1995.tb02929.x | doi=10.1111/j.1365-2265.1995.tb02929.x | accessdate=2015-06-12}}</ref><ref name="Frenkel Silbergeld Deghenghi Laron 1995">{{cite journal | last=Frenkel | first=J. | last2=Silbergeld | first2=A. | last3=Deghenghi | first3=R. | last4=Laron | first4=Z. | title=Short Term Effect of Intranasal Administration of Hexarelin | journal=Journal of Pediatric Endocrinology and Metabolism | publisher=Walter de Gruyter (GmbH) | volume=8 | issue=1 | year=1995 | url=https://dx.doi.org/10.1515/JPEM.1995.8.1.43 | doi=10.1515/jpem.1995.8.1.43 | accessdate=2015-06-12}}</ref> Examorelin does not affect plasma levels of [[glucose]], [[luteinizing hormone]] (LH), [[follicle-stimulating hormone]] (FSH), or [[thyroid-stimulating hormone]] (TSH) in humans.<ref name="Imbimbo Mant Edwards Amin 1994" />

 
Examorelin releases more GH than does [[growth hormone-releasing hormone]] (GHRH) in humans,<ref name="Arvat Vito Maccagno Broglio 1997 pp. 885–891" /><ref name="Maccario Arvat Procopio Gianotti 1995 pp. 134–138">{{cite journal | last=Maccario | first=M. | last2=Arvat | first2=E. | last3=Procopio | first3=M. | last4=Gianotti | first4=L. | last5=Grottoli | first5=S. | last6=Imbimbo | first6=B.P. | last7=Lenaerts | first7=V. | last8=Deghenghi | first8=R. | last9=Camanni | first9=F. | last10=Ghigo | first10=E. | title=Metabolic modulation of the growth hormone-releasing activity of hexarelin in man | journal=Metabolism | publisher=Elsevier BV | volume=44 | issue=1 | year=1995 | pages=134–138 | url=https://dx.doi.org/10.1016/0026-0495(95)90300-3 | doi=10.1016/0026-0495(95)90300-3 | accessdate=2015-06-12}}</ref> and produces synergistic effects on GH release in combination with GHRH, resulting in "massive" increases in plasma GH levels even with only low doses of examorelin.<ref name="Massoud Hindmarsh Brook 1996 pp. 4338–4341">{{cite journal | last=Massoud | first=A F | last2=Hindmarsh | first2=P C | last3=Brook | first3=C G | title=Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. | journal=The Journal of Clinical Endocrinology| publisher=The Endocrine Society | volume=81 | issue=12 | year=1996 | pages=4338–4341 | url=https://dx.doi.org/10.1210/jcem.81.12.8954038 | doi=10.1210/jcem.81.12.8954038 | accessdate=2015-06-12}}</ref><ref name="Arvat Vito Gianotti Ramunni 1997 pp. 83–88">{{cite journal | last=Arvat | first=Emanuela | last2=Vito | first2=Lidia Di | last3=Gianotti | first3=Laura | last4=Ramunni | first4=Josefina | last5=Boghen | first5=Muni F. | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Mechanisms underlying the negative growth hormone (GH) | journal=Metabolism | publisher=Elsevier BV | volume=46 | issue=1 | year=1997 | pages=83–88 | url=https://dx.doi.org/10.1016/S0026-0495(97)90173-6 | doi=10.1016/s0026-0495(97)90173-6 | accessdate=2015-06-12}}</ref><ref name="Arvat Gianotti Vito Imbimbo 1995 pp. 51–56">{{cite journal | last=Arvat | first=Emanuela | last2=Gianotti | first2=Laura | last3=Vito | first3=Lidia Di | last4=Imbimbo | first4=Bruno P. | last5=Lenaerts | first5=Vincent | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man | journal=Neuroendocrinology | publisher=S. Karger (AG) | volume=61 | issue=1 | year=1995 | pages=51–56 | url=https://dx.doi.org/10.1159/000126827 | doi=10.1159/000126827 | accessdate=2015-06-12}}</ref> Pre-administration of GH blunts the GH-releasing effect of examorelin, while, in contrast, fully abolishing the effect of GHRH.<ref name="Arvat Vito Gianotti Ramunni 1997 pp. 83–88" /><ref name="Massoud Hindmarsh Brook 1995 pp. 617–621">{{cite journal | last=Massoud | first=Ahmed F. | last2=Hindmarsh | first2=Peter C. | last3=Brook | first3=Charles G. D. | title=Hexarelin induced growth hormone release is influenced by exogenous growth hormone | journal=Clinical Endocrinology | publisher=Wiley-Blackwell | volume=43 | issue=5 | year=1995 | pages=617–621 | url=https://dx.doi.org/10.1111/j.1365-2265.1995.tb02927.x | doi=10.1111/j.1365-2265.1995.tb02927.x | accessdate=2015-06-12}}</ref> Pre-treatment with IGF-1 also blunts the GH-elevating effect of examorelin.<ref name="Owusu-Apenten2010">{{cite book|author=Richard Owusu-Apenten|title=Bioactive Peptides: Applications for Improving Nutrition and Health|url=https://books.google.com/books?id=JJ_MBQAAQBAJ&pg=PA292|date=23 June 2010|publisher=CRC Press|isbn=978-1-4398-1363-8|pages=292–}}</ref> [[Testosterone (medication)|Testosterone]], [[testosterone enanthate]], and [[ethinylestradiol]], though not [[oxandrolone]], have been found to significantly potentiate the GH-releasing effects of examorelin in humans.<ref name="pmid9062497">{{cite journal |vauthors=Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, etal | title=The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. | journal=J Clin Endocrinol Metab | year= 1997 | volume= 82 | issue= 3 | pages= 861–4 | pmid=9062497 | doi=10.1210/jcem.82.3.3795 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9062497}}</ref><ref name="Loche Cambiaso Carta Setzu 1995 pp. 674–678">{{cite journal | last=Loche | first=S | last2=Cambiaso | first2=P | last3=Carta | first3=D | last4=Setzu | first4=S | last5=Imbimbo | first5=B P | last6=Borrelli | first6=P | last7=Pintor | first7=C | last8=Cappa | first8=M | title=The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. | journal=The Journal of Clinical Endocrinology | publisher=The Endocrine Society | volume=80 | issue=2 | year=1995 | pages=674–678 | url=https://dx.doi.org/10.1210/jcem.80.2.7852535 | doi=10.1210/jcem.80.2.7852535 | accessdate=2015-06-12}}</ref> In accordance, likely due to increases in [[sex steroid]] levels, [[puberty]] has also been found to significantly augment the GH-elevating actions of examorelin in humans.<ref name="Bellone Aimaretti Bartolotta Benso 1995 pp. 1090–1094">{{cite journal | last=Bellone | first=J | last2=Aimaretti | first2=G | last3=Bartolotta | first3=E | last4=Benso | first4=L | last5=Imbimbo | first5=B P | last6=Lenhaerts | first6=V | last7=Deghenghi | first7=R | last8=Camanni | first8=F | last9=Ghigo | first9=E | title=Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. | journal=The Journal of Clinical Endocrinology| publisher=The Endocrine Society | volume=80 | issue=4 | year=1995 | pages=1090–1094 | url=https://dx.doi.org/10.1210/jcem.80.4.7714074 | doi=10.1210/jcem.80.4.7714074 | accessdate=2015-06-12}}</ref>

 
A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50–75% decrease in efficacy over the course of weeks to months).<ref name="pmid9589671">{{cite journal | vauthors = Rahim A, O'Neill PA, Shalet SM | title = Growth hormone status during long-term hexarelin therapy | journal = J. Clin. Endocrinol. Metab. | volume = 83 | issue = 5 | pages = 1644–9 | year = 1998 | pmid = 9589671 | doi = 10.1210/jcem.83.5.4812 | url = http://press.endocrine.org/doi/10.1210/jcem.83.5.4812?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed}}</ref><ref name="Ghigo1999">{{cite book|author=Ezio Ghigo|title=Growth Hormone Secretagogues: Basic Findings and Clinical Implications|url=https://books.google.com/books?id=pDabYbzcGSQC&pg=PA178|year=1999|publisher=Elsevier|isbn=978-0-444-82933-7|pages=178–}}</ref>
